Keytruda® for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 (tumour proportion score [TPS] ≥ 50%) with no EGFR or ALK positive tumour mutations and no prior systemic therapy for advanced disease.
|NCPE Assessment Process||Ongoing|
|Rapid review received||19/12/2016|
|Rapid review completed||10/01/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended|
|Full pharmacoeconomic assessment commissioned by HSE||11/01/2017|
|Pre-submission consultation with Applicant||23/01/2017|
|Submission received from Applicant||10/04/2017|
|Preliminary review sent to Applicant||04/07/2017|
|NCPE assessment re-commenced||02/08/2017|
|Applicant Factual Accuracy Check||06/10/2017|
|NCPE assessment re-commenced||11/10/2017|
|NCPE assessment completed||13/10/2017|
|Full pharmacoeconomic assessment outcome||Reimbursement not recommended at the submitted price|
The HSE has approved reimbursement following confidential price negotiations; April 2018.